Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression

Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease

(2013) Regina Kunz et al.   ANNALS OF INTERNAL MEDICINE

Inhibition of the renin–angiotensin–aldosterone system

(2012) Massimo Volpe et al.   JOURNAL OF HYPERTENSION

Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression

(2011) Cesar Cerezo et al.   JOURNAL OF HYPERTENSION

Current challenges in the clinical management of hypertension

(2011) Luis M. Ruilope   Nature Reviews Cardiology

Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes

(2011) Hermann Haller et al.   NEW ENGLAND JOURNAL OF MEDICINE

ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations

(2010) Luis M Ruilope et al.   EXPERT OPINION ON PHARMACOTHERAPY

How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?

(2010) Finn Gustafsson et al.   JOURNAL OF HYPERTENSION

Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms

(2010) Faiez Zannad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis

(2009) P. Verdecchia et al.   EUROPEAN HEART JOURNAL

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes: A prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT)

(2008) P. Ruggenenti et al.   DIABETES CARE

Renin-angiotensin blockade and kidney disease

(2008) Pantelis A Sarafidis et al.   LANCET

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial

(2008) Johannes FE Mann et al.   LANCET

Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy

(2008) Hans-Henrik Parving et al.   NEW ENGLAND JOURNAL OF MEDICINE